CPX-351 vs. conventional chemotherapy cardiotoxicity in high-risk AML: A post hoc phase III trial analysis

Authors

• Joshua D Mitchell, Washington University School of Medicine in St. Louis
• Michael Pfeiffer, Penn State
• John Boehmer, Penn State
• John Gorcsan, Penn State
• Shunsuke Eguchi, Penn State
• Yoshiyuki Orihara, Penn State
• Nalina Dronamraju, Jazz Pharmaceuticals Plc
• Sonja Dhani, Jazz Pharmaceuticals Plc
• Stefan Faderl, Jazz Pharmaceuticals Plc
• Tara L Lin, University of Kansas
• Geoffrey L Uy, Washington University School of Medicine in St. Louis
• Jeffrey E Lancet, H. Lee Moffitt Cancer Center and Research Institute
• Jorge E Cortes, Georgia Cancer Center at Augusta University

Journal

Cardiooncology

Publication Date

11-25-2025

Volume

12

Issue

1

First Page

6

Document Type

Open Access Publication

DOI

10.1186/s40959-025-00421-7

Rights and Permissions

Mitchell, J.D., Pfeiffer, M., Boehmer, J. et al. CPX-351 vs. conventional chemotherapy cardiotoxicity in high-risk AML: a post hoc phase III trial analysis. Cardio-Oncology 12, 6 (2026). https://doi.org/10.1186/s40959-025-00421-7 This article is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License, which permits any non-commercial use, sharing, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if you modified the licensed material. You do not have permission under this licence to share adapted material derived from this article or parts of it. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by-nc-nd/4.0/.

Recommended Citation

Mitchell, Joshua D; Pfeiffer, Michael; Boehmer, John; Gorcsan, John; Eguchi, Shunsuke; Orihara, Yoshiyuki; Dronamraju, Nalina; Dhani, Sonja; Faderl, Stefan; Lin, Tara L; Uy, Geoffrey L; Lancet, Jeffrey E; and Cortes, Jorge E, "CPX-351 vs. conventional chemotherapy cardiotoxicity in high-risk AML: A post hoc phase III trial analysis." Cardiooncology. 12, 1. 6 (2025).
https://digitalcommons.wustl.edu/oa_4/6729

Department

ICTS (Institute of Clinical and Translational Sciences)

Additional Links

Supplemental material is available for this article at publisher site.